Talus Bio launches Tech Access Program to chart the human regulome

Talus Bio launches Tech Access Program to chart the human regulome

Seattle, WA – July 7, 2025 – Talus Bioscience, a biotechnology company pioneering Native Regulome Profiling for drug discovery recently announced the launch of the Regulome Early Access Program. The program invites researchers working at the frontier of biology to collaborate with Talus Bio in mapping the dynamic protein-DNA regulatory network.

Through this exclusive program, Talus Bio will partner with a small number of academic and industry research groups to offer free access to Native Regulome Profiling, the first technology capable of measuring the activity of the over 4,000 genome-regulating proteins in their natural cellular context and over time.

“The regulome is the cell’s decision-making system,” said Alex Federation, PhD, CEO and Co-Founder of Talus Bio. “With this program, we’re opening up the tools we use internally to others working on some of the most complex, unsolved questions in biology. We use these tools for drug discovery, but they have applications broadly, from gene-environment interactions, to characterizing poorly-understood disease states, to building new synthetic gene circuits. 

Participants in the Regulome Early Access Program will receive:

• Free Native Regulome Profiling in their system of interest
• Access to Talus Bio’s AI-powered analysis pipeline
• Direct 1-on-1 collaboration with the Talus Bio platform team

All resulting datasets will be open-sourced to the community, accelerating collective progress toward understanding and therapeutically targeting transcriptional regulation.

The program is designed to support groundbreaking work in:

• Pathological gene regulation in disease
• Environmental and chemical perturbation responses
• Synthetic and systems biology
• New frontiers in genome regulation

“We believe this is a truly unique technology, and now that we've really hit our pace with platform capacity, we want to use some of that throughput to collaborate with the broader scientific community,” said Lindsay Pino, PhD, CTO and Co-Founder of Talus Bio. “By partnering with innovative collaborators, we aim to use this platform to push the boundaries of chromatin biology, gene regulation, and nuclear regulome science.”

The launch of the Regulome Early Access Program builds on Talus Bio’s recent momentum, including a recent funding round led by Two Bear Capital, and ongoing development of the company’s flagship technology  platform for transcription factor drug discovery.

Researchers interested in participating can learn more and apply here.

‍

About Talus Bioscience, Inc.

Founded in 2020 by Alex Federation, PhD, and Lindsay Pino, PhD, Talus Bio is pioneering the development of therapeutics that target transcription factors—the central regulators of gene expression long considered "undruggable." The Seattle-based company’s MARMOT platform combines AI, next-gen proteomics, and synthetic chemistry to profile, discover, and optimize small molecules that modulate transcription factor activity in live cells. With the world’s largest dataset of transcription factor activity and a team of experts in machine learning, biochemistry, and systems biology, Talus Bio is redefining what’s possible in drug discovery.

‍

Media Contact:

Michelle Briscoe, COO & CFO

Talus Bioscience

admin@talus.bio

‍